Show simple item record

dc.contributor.authorDubois, FPB
dc.contributor.authorShapira, O
dc.contributor.authorGreenwald, NF
dc.contributor.authorZack, T
dc.contributor.authorWala, J
dc.contributor.authorTsai, JW
dc.contributor.authorCrane, A
dc.contributor.authorBaguette, A
dc.contributor.authorHadjadj, D
dc.contributor.authorHarutyunyan, AS
dc.contributor.authorKumar, KH
dc.contributor.authorBlattner-Johnson, M
dc.contributor.authorVogelzang, J
dc.contributor.authorSousa, C
dc.contributor.authorKang, KS
dc.contributor.authorSinai, C
dc.contributor.authorWang, DK
dc.contributor.authorKhadka, P
dc.contributor.authorLewis, K
dc.contributor.authorNguyen, L
dc.contributor.authorMalkin, H
dc.contributor.authorHo, P
dc.contributor.authorO'Rourke, R
dc.contributor.authorZhang, S
dc.contributor.authorGold, R
dc.contributor.authorDeng, D
dc.contributor.authorSerrano, J
dc.contributor.authorSnuderl, M
dc.contributor.authorJones, C
dc.contributor.authorWright, KD
dc.contributor.authorChi, SN
dc.contributor.authorGrill, J
dc.contributor.authorKleinman, CL
dc.contributor.authorGoumnerova, LC
dc.contributor.authorJabado, N
dc.contributor.authorJones, DTW
dc.contributor.authorKieran, MW
dc.contributor.authorLigon, KL
dc.contributor.authorBeroukhim, R
dc.contributor.authorBandopadhayay, P
dc.coverage.spatialEngland
dc.date.accessioned2022-09-27T13:58:56Z
dc.date.available2022-09-27T13:58:56Z
dc.date.issued2022-06-01
dc.identifier10.1038/s43018-022-00403-z
dc.identifier.citationNature Cancer, 2022, 3 (8), pp. 994 - 1011en_US
dc.identifier.issn2662-1347
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5509
dc.identifier.eissn2662-1347
dc.identifier.eissn2662-1347
dc.identifier.doi10.1038/s43018-022-00403-z
dc.description.abstractWe analyzed the contributions of structural variants (SVs) to gliomagenesis across 179 pediatric high-grade gliomas (pHGGs). The most recurrent SVs targeted MYC isoforms and receptor tyrosine kinases (RTKs), including an SV amplifying a MYC enhancer in 12% of diffuse midline gliomas (DMG), indicating an underappreciated role for MYC in pHGG. SV signature analysis revealed that tumors with simple signatures were TP53 wild type (TP53WT) but showed alterations in TP53 pathway members PPM1D and MDM4. Complex signatures were associated with direct aberrations in TP53, CDKN2A and RB1 early in tumor evolution and with later-occurring extrachromosomal amplicons. All pHGGs exhibited at least one simple-SV signature, but complex-SV signatures were primarily restricted to subsets of H3.3K27M DMGs and hemispheric pHGGs. Importantly, DMGs with complex-SV signatures were associated with shorter overall survival independent of histone mutation and TP53 status. These data provide insight into the impact of SVs on gliomagenesis and the mechanisms that shape them.
dc.formatPrint-Electronic
dc.format.extent994 - 1011
dc.languageeng
dc.language.isoengen_US
dc.publisherOXFORD UNIV PRESS INCen_US
dc.relation.ispartofNature Cancer
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectBrain Neoplasms
dc.subjectCell Cycle Proteins
dc.subjectChild
dc.subjectGlioma
dc.subjectHistones
dc.subjectHumans
dc.subjectMutation
dc.subjectProto-Oncogene Proteins
dc.titleStructural variants shape driver combinations and outcomes in pediatric high-grade glioma.en_US
dc.typeJournal Article
dcterms.dateAccepted2022-05-23
dc.date.updated2022-09-27T13:56:23Z
rioxxterms.versionAMen_US
rioxxterms.versionofrecord10.1038/s43018-022-00403-zen_US
rioxxterms.licenseref.startdate2022-06-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35788723
pubs.issue8
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1038/s43018-022-00403-z
pubs.volume3
icr.researchteamGlioma Teamen_US
dc.contributor.icrauthorJones, Chris
icr.provenanceDeposited by Mr Arek Surman on 2022-09-27. Deposit type is initial. No. of files: 1. Files: Structural_variants_shape_driver_combinations_and_.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record